Darren Hodgson
AstraZeneca (United Kingdom)(GB)University of Toronto(CA)Princess Margaret Cancer Centre(CA)AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Melanoma and MAPK Pathways, Cancer Genomics and Diagnostics, BRCA gene mutations in cancer, Computational Drug Discovery Methods
Most-Cited Works
- → Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial(2014)1,433 cited
- → Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial(2016)446 cited
- → Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial(2018)406 cited
- → Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA(2023)313 cited
- → Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer(2015)290 cited